The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (Q34470502)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma |
scientific article |
Statements
1 reference
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (English)
1 reference
John C Byrd
1 reference
Kristie A Blum
1 reference
Jeffrey A Jones
1 reference
Mitch A Phelps
1 reference
Robert A Baiocchi
1 reference
Ming Poi
1 reference
Kami Maddocks
1 reference
Pierluigi Porcu
1 reference
Beth A Christian
1 reference
Joseph M Flynn
1 reference
Don M Benson
1 reference
Lai Wei
1 reference
William A Wegener
1 reference
David M Goldenberg
1 reference
7 April 2015
1 reference
1 reference
169
1 reference
5
1 reference
701-710
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference